Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Trial Profile

Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aravive S6 (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2019 According to an Aravive media release, the company expects to present data from 30 patients (10 mg/kg dose) from this trial towards the end of the year 2019. This analysis will inform the regulatory strategy for AVB-500 as a treatment for platinum-resistant ovarian cancer.
    • 27 Sep 2019 Preliminary results (n=28) presented in the Aravive media release.
    • 23 Sep 2019 Planned End Date changed from 31 Oct 2026 to 28 Feb 2027.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top